SLC6A3 and attention deficit-hyperactivity disorder: Recent studies have focused on DAT hypofunction, demonstrating that the heterozygote deletion of the transporter, both in mice [62] and in rats [24], is relevant to neuropsychiatric disorders, like attention-deficit, hyperactivity disorder (ADHD), and vulnerability to stress.